amsacrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
acridine derivatives	203	51264-14-3

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

amsacrine
acridinylanisidide
amekrin
amsidil
amsidine
amsidyl
lamasine

An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.

Molecular weight: 393.46
Formula: C21H19N3O3S
CLOGP: 4.54
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 80.32
ALOGS: -5.09
ROTB: 4

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	10.05 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	4.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.03 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1987	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute myeloid leukaemia recurrent	85.91	70.37	14	399	1376	50603335
Graft versus host disease	76.55	70.37	16	397	6150	50598561
Systemic inflammatory response syndrome	73.77	70.37	15	398	5034	50599677

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute myeloid leukaemia recurrent	124.66	113.06	21	329	1759	29572418

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute myeloid leukaemia recurrent	164.21	69.37	28	664	2756	64495284
Venoocclusive liver disease	122.85	69.37	27	665	9988	64488052

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01XX01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:50750	inhibitors of type II topoisomerase
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D007202	Indicators and Reagents
MeSH PA	D007364	Intercalating Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.98	acidic
pKa2	8.25	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
DNA topoisomerase II	Enzyme	P11388 Q02880	TOP2A_HUMAN TOP2B_HUMAN		EC50	6.14		CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	6.68		CHEMBL
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		Ki	5.12		WOMBAT-PK
DNA topoisomerase 2-alpha	Enzyme	P11388	TOP2A_HUMAN		IC50	5		CHEMBL
DNA topoisomerase I, mitochondrial	Enzyme	Q969P6	TOP1M_HUMAN		IC50	7.43		WOMBAT-PK
DNA topoisomerase 1	Enzyme	P11387	TOP1_HUMAN		IC50	7.43		WOMBAT-PK
DNA topoisomerase 2-beta	Enzyme	Q02880	TOP2B_HUMAN		EC50	4.96		CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	5.30		CHEMBL

External reference:

ID	Source
4025233	VUID
N0000171765	NUI
D02321	KEGG_DRUG
151347	RXNORM
C0002699	UMLSCUI
CHEBI:2687	CHEBI
ASW	PDB_CHEM_ID
CHEMBL43	ChEMBL_ID
DB00276	DRUGBANK_ID
D000677	MESH_DESCRIPTOR_UI
2179	PUBCHEM_CID
4864	INN_ID
00DPD30SOY	UNII
003469	NDDF
4025233	VANDF
326955000	SNOMEDCT_US
391774005	SNOMEDCT_US

Pharmaceutical products:

None